


Life Sciences

2013: Recognized both globally and nationally as a leading life sciences practice, WilmerHale has four decades of experience representing biotechnology, pharmaceutical and medical device companies at all stages of growth, as well as venture capitalists and investment banks. We have represented life sciences clients in venture financings, public offerings, mergers and acquisitions, and licensing agreements and collaborations; protected their innovations through patent prosecution and portfolio development; defended their interests in enterprise-critical patent litigation; and navigated regulatory issues vital to their success. The following is a selection of our recent life sciences transactions.

Counsel of Choice to Life Sciences Innovators

SERVING INDUSTRY LEADERS IN BIOTECHNOLOGY, PHARMACEUTICALS, MEDICAL DEVICES AND BEYOND



Mergers and Acquisitions

 <p>Acquisition of One Lambda \$925,000,000 September 2012</p>	 <p>Acquisition by Bausch + Lomb \$500,000,000 June 2012</p>	 <p>Acquisition of Incline Therapeutics \$390,000,000 (including milestone payments) January 2013</p>	 <p>Agreement to be acquired by Cynosure \$294,000,000 March 2013</p>	
 <p>Global alliance and acquisition of Recothrom® assets of Bristol Myers Squibb \$115,000,000 February 2013</p>	 <p>Acquisition by Alexion Pharmaceuticals \$1,080,000,000 (including milestone payments) February 2012</p>	 <p>Acquisition by Biogen Idec \$562,500,000 (including milestone payments) March 2012</p>	 <p>Acquisition of Liqent \$72,000,000 December 2012</p>	 <p>Acquisition by Boston Scientific \$265,000,000 (including milestone payments) October 2012</p>

Public Offerings

 <p>Public Offering of Common Stock \$465,100,000 Counsel to Underwriters May 2012</p>	 <p>Initial Public Offering of Common Stock \$63,250,000 Counsel to Issuer January 2012</p>	 <p>Public Offering of Common Stock \$41,837,000 Counsel to Issuer August 2012</p>	 <p>Initial Public Offering of Common Stock \$105,297,000 Counsel to Issuer April 2012</p>	
 <p>Rule 144A Placement of 3.25% Convertible Senior Notes \$120,000,000 Counsel to Issuer January 2013</p>	 <p>Public Offering of Common Stock \$202,400,000 Counsel to Issuer August 2012</p>	 <p>Initial Public Offering of Common Stock \$77,625,000 Counsel to Issuer July 2012</p>	 <p>Public Offerings of Common Stock \$260,878,000 Counsel to Issuer August and December 2012</p>	 <p>Public Offering of 5.00% Senior Notes \$500,000,000 Counsel to Issuer October 2011</p>

Strategic Alliances and Collaborations

 <p>Settlement and licensing agreements to resolve ANDA litigation</p>	 <p>Restructuring of collaborations with Intellikine/Millennium and Purdue/Mundipharma</p>	 <p>Collaboration with Boehringer Ingelheim to develop digital diabetes self-management programs</p>	 <p>Licensing and manufacturing agreements</p>	 <p>Collaboration with Genzyme on RNAi therapeutics for transthyretin-mediated amyloidosis in Asia</p>
 <p>Collaboration with Mersana Therapeutics on antibody-drug conjugates</p>	 <p>Drug development and commercialization agreements</p>	 <p>Collaboration with Jazz Pharmaceuticals to develop deuterated sodium oxybate products for narcolepsy</p>	 <p>Collaboration with Menarini Group for antibody-based cancer drugs</p>	

Venture Capital Financings

 <p>\$20,500,000 (\$45,000,000 total) First Round April 2012</p>	 <p>\$37,000,000 Second Round April 2012</p>	 <p>\$10,000,000 First Round December 2012</p>	 <p>\$11,000,000 First Round July 2012</p>	 <p>\$30,000,000 Late Stage May 2012</p>
 <p>\$36,000,000 Late Stage November 2012</p>	 <p>\$28,000,000 Fourth Round December 2012</p>	 <p>\$12,000,000 Second Round June 2012</p>	 <p>\$18,000,000 First Round July 2012</p>	



Mixed Sources
Product group from well-managed
forests, controlled sources and
recycled wood or fiber
www.fsc.org Cert no. BV-COC-070904
© 1996 Forest Stewardship Council

13_0333 RPI 4/13 2500

WilmerHale recognizes its corporate responsibility to environmental stewardship.

wilmerhale.com

Wilmer Cutler Pickering Hale and Dorr LLP is a Delaware limited liability partnership. WilmerHale principal law offices: 60 State Street, Boston, Massachusetts 02109, +1 617 526 6000; 1875 Pennsylvania Avenue, NW, Washington, DC 20006, +1 202 663 6000. Our United Kingdom offices are operated under a separate Delaware limited liability partnership of solicitors and registered foreign lawyers authorized and regulated by the Solicitors Regulation Authority (SRA No. 287488). Our professional rules can be found at www.sra.org.uk/solicitors/code-of-conduct.page. A list of partners and their professional qualifications is available for inspection at our UK offices. In Beijing, we are registered to operate as a Foreign Law Firm Representative Office. This material is for general informational purposes only and does not represent our advice as to any particular set of facts; nor does it represent any undertaking to keep recipients advised of all legal developments. Prior results do not guarantee a similar outcome. © 2013 Wilmer Cutler Pickering Hale and Dorr LLP